Dilation of the ascending aorta in Turner syndrome - a prospective cardiovascular magnetic resonance study

Table 1 Demographics and descriptives in Turner syndrome and controls

	Turner syndrome		Controls
	n = 80		n = 67
Baseline age (years [range])	38 ± 10 [18 - 60]		39 ± 12 [20 - 63] ***
Body surface area (m²)	1.5 ± 0.2		1.8 ± 0.2 **
Karyotype (45X/non-45X, %)	60%/40%		-
Growth hormone substitution ^a
Treated (%)	28%		-
Exposure time (years)	5 ± 3		-
Estrogen substitution ^a
Treated (%)	85%		-
Exposure time (years)	19 ± 9		-
Aortic abnormalities
Elongated transverse aortic arch	48%		-
Aortic coarctation	11%		-
Previous coarctation repair	9%		-
Aortic arch hypoplasia	2%		-
Bovine aortic arch	8%		8%
Aberrant right subclavian artery	10%		-
	Baseline	Follow-up
Antihypertensive treatment	30%	46%
Ambulatory blood pressure
24-hour systolic (mm Hg)	122 ± 14	120 ± 12 *	113 ± 11 **
24-hour diastolic (mm Hg)	78 ± 11	76 ± 9 *	71 ± 8 **
24-hour heart rate (beats/min)	77 ± 9	75 ± 8 *	71 ± 9 **

Continuous variable are expressed as means ± standard deviations.
* P < 0.05 using Student's paired t-test to compare Turner syndrome at baseline and follow-up.
** P < 0.05 using Student's independent t-test to compare Turner syndrome at baseline to controls.
*** P > 0.05 using Student's independent t-test to compare Turner syndrome at baseline to controls

ISSN: 1532-429X